Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.60%, ranking 8th among 31 primary industries, outperforming the CSI 300 index which rose by 2.18% [4][16] - The PE (TTM overall method, excluding negative values) for the pharmaceutical and biotechnology industry as of January 9, 2026, is 30.56x, up from 29.20x at the end of the previous period, indicating an upward valuation trend [4][21] - The top three sub-industries in terms of PE are vaccines (47.64x), hospitals (43.33x), and medical devices (39.44x), while pharmaceutical circulation has the lowest valuation at 15.42x [4][21] Industry Review - The report highlights significant developments in the pharmaceutical sector, including the release of the "Fourth Batch of Encouraged Generic Drug Catalog" aimed at optimizing the drug supply guarantee system and enhancing industry structure [6][26] - The report notes that 43 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 2.779 billion yuan, with 8 companies increasing holdings by 20 million yuan and 35 companies reducing holdings by 2.799 billion yuan [4] Important Industry News - The National Health Commission and other departments released the "Fourth Batch of Encouraged Generic Drug Catalog," which includes 21 varieties and 47 specifications, focusing on clinical needs and disease burdens [26][27] - The NMPA announced measures to strengthen the supervision and management of entrusted drug production, aiming to enhance drug quality assurance levels [29][30] - The NMPA also optimized the review and approval process for urgently needed overseas drugs, encouraging simultaneous global development and submission [31][32] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with strong pipeline differentiation, rapid clinical advancement, and robust overseas collaboration capabilities [7][8] - In the medical device sector, it recommends paying attention to companies with solid technical foundations and deep collaborations with leading hospitals and research institutions [8]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-7535 tablets, a new oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1]. Group 1: Product Development - The clinical trial approval for HRS-7535 tablets will allow the company to initiate trials in the near future [1]. - HRS-7535 functions by activating GLP-1 receptors, which promotes insulin secretion from the pancreas, reduces glucagon secretion, and inhibits gastric emptying [1]. - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to reduced energy intake [1]. Group 2: Market Implications - The introduction of HRS-7535 could provide a new treatment option for type 2 diabetes (T2DM) patients, addressing both glycemic control and weight management [1].

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] Group 1: Product Development - SHR-1826 is intended for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer that is c-Met overexpressing (2-3+, ≥50%) and has failed at least one line of systemic therapy [1]

恒瑞医药公告称，子公司山东盛迪医药收到国家药监局关于HRS - 7535片的《药物临床试验批准通知 书》，将于近期开展临床试验。该药物拟用于高血压合并超重或肥胖治疗，是新型口服小分子胰高血糖 素样肽 - 1受体激动剂，全球尚无同类口服药上市。截至目前，相关项目累计研发投入约3.69亿元。药 品研发到上市周期长、环节多，存在不确定性，公司将推进项目并披露进展。 ...

Group 1 - The core point of the article is that Heng Rui Medicine's injectable SHR-1826 has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] Group 2 - The announcement was made by Heng Rui Medicine, specifically through its subsidiary Suzhou Sediya Biopharmaceutical Co., Ltd [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] Company Summary - Heng Rui Medicine (600276.SH) announced the inclusion of its injectable SHR-1826 in the breakthrough therapy list by the NMPA [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 7.29 | 11.98% | 167.84万 | | 11.97亿 | | 000766 | 通化金马 | 27.87 | 9.98% | 46.86万 | | 12.97亿 | | 002940 | 昂利康 | 38.66 | 7.87% | 25.79万 | | 9.79亿 | | 300401 | 化园生物 | 17.36 | 5.60% | - 54.32万 | | 2666 | | 920367 | 新赣江 | 23.50 | 5.48% | 5.45万 | | 1.26亿 | | 688176 | 亚虹医药 | 12.60 | 5.09% | 19.90万 | | 2.45亿 | | 301281 | 科源制药 | 30.83 | 5.08% | 4.03万 | | 1.22亿 | | 000908 | *ST景峰 | 8.19 | 5.00% | 3.17万 | | 2599.61万 | ...

Group 1 - The core point of the article is that Hengrui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval for the environmental impact assessment of its Phase II construction project, with a total investment of 250 million yuan [1] - The "A-share Green Report" project aims to enhance the transparency of environmental information for listed companies, utilizing authoritative environmental regulatory data from 31 provinces and 337 cities [1] - The project includes monitoring the environmental performance of listed companies and their subsidiaries, providing professional data analysis and insights, and regularly updating the environmental risk rankings of these companies [1] Group 2 - The latest A-share Green Weekly Report (Issue No. 228) indicates that four listed companies have recently exposed environmental risks [1]

Core Viewpoint - The report highlights the AH premium rates of various stocks, indicating significant discrepancies between their H-shares and A-shares, with some stocks showing extremely high premiums while others exhibit negative premiums. Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 770.97% with a deviation value of -104.86% [1] - Zhejiang Shibao (01057) follows with a premium rate of 432.48% and a deviation value of 91.33% [1] - Nanjing Panda Electronics (00553) ranks third with a premium rate of 288.23% and a deviation value of 78.28% [1] Group 2: Bottom AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -12.93% with a deviation value of -2.96% [1] - China Merchants Bank (03968) has a premium rate of -2.18% and a deviation value of -0.26% [1] - Heng Rui Medicine (01276) shows a premium rate of -0.61% with a deviation value of -1.85% [1] Group 3: Top Deviation Values - Zhejiang Shibao (01057) leads in deviation value at 91.33% with a premium rate of 432.48% [2] - Goldwind Technology (02208) has a deviation value of 80.21% with a premium rate of 142.96% [2] - Nanjing Panda Electronics (00553) ranks third in deviation value at 78.28% with a premium rate of 288.23% [2] Group 4: Bottom Deviation Values - Northeast Electric (00042) has the lowest deviation value at -104.86% despite a high premium rate of 770.97% [3] - Morning Paper (01812) shows a deviation value of -45.19% with a premium rate of 201.16% [3] - Nanhua Futures (02691) has a deviation value of -27.51% with a premium rate of 102.69% [3]

Investment Rating - The report maintains a positive outlook on innovative drugs and the related industry chain, indicating potential value revaluation for specific pharmaceutical companies [6][28]. Core Insights - The pharmaceutical sector in A-shares showed strong performance in the second week of January 2026, with the SW Pharma Bio index rising by 7.8%, outperforming the overall market [8][29]. - Key sub-sectors such as medical services (+12.3%), medical equipment (+9.4%), and chemical preparations (+7.3%) demonstrated significant growth during this period [13][29]. - Notable individual stock performances included Innovative Medical Management (+61.0%), Sanbo Hospital Management Group (+56.2%), and MeHow Medical (+56.1%) [15][29]. - The report highlights a normal premium level of 68.3% for the pharmaceutical sector relative to all A-shares as of January 9, 2026 [15][23]. Summary by Sections 1. Continued Focus on Innovative Drugs and Industry Chain - The report emphasizes the high prosperity in innovative drugs and suggests monitoring companies like Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical for potential value revaluation [6][28]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of January 2026, the A-share pharmaceutical sector outperformed the market, with the SW Pharma Bio index increasing by 7.8% [8][29]. - The report ranks the pharmaceutical sector as the 5th best-performing industry among Shenwan's primary industries during this period [11][29]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector outperformed the market, with the Hang Seng Healthcare index rising by 10.3% and the biotechnology sector increasing by 11.1% [20][29]. - Conversely, the U.S. pharmaceutical sector underperformed, with the S&P Healthcare Select Sector rising by only 1.1% compared to the S&P 500's 1.6% increase [20][29].